[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,577,506
  • Shares Outstanding, K 124,238
  • Annual Sales, $ 88,040 K
  • Annual Income, $ -784,960 K
  • EBIT $ -612 M
  • EBITDA $ -602 M
  • 60-Month Beta 0.38
  • Price/Sales 93.21
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 53.59% (-15.28%)
  • Historical Volatility 58.69%
  • IV Percentile 20%
  • IV Rank 5.77%
  • IV High 183.58% on 05/04/26
  • IV Low 45.63% on 06/09/25
  • Expected Move (DTE 8) 4.73 (6.31%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 12,047
  • Volume Avg (30-Day) 8,104
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 145,827
  • Open Int (30-Day) 132,016
  • Expected Range 70.11 to 79.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.67
  • Number of Estimates 8
  • High Estimate $-1.53
  • Low Estimate $-1.80
  • Prior Year $-1.12
  • Growth Rate Est. (year over year) -49.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.65 +27.62%
on 04/29/26
80.20 -6.68%
on 05/05/26
+9.90 (+15.24%)
since 04/06/26
3-Month
58.43 +28.08%
on 03/13/26
80.20 -6.68%
on 05/05/26
+12.50 (+20.05%)
since 02/06/26
52-Week
29.31 +155.34%
on 05/15/25
80.20 -6.68%
on 05/05/26
+40.87 (+120.31%)
since 05/06/25

Most Recent Stories

More News
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common...

CYTK : 74.84 (-2.92%)
Cytokinetics: Q1 Earnings Snapshot

Cytokinetics: Q1 Earnings Snapshot

CYTK : 74.84 (-2.92%)
Cytokinetics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $650 million...

CYTK : 74.84 (-2.92%)
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

U.S. Launch of MYQORZO ® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ...

CYTK : 74.84 (-2.92%)
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance  With Consistent Positive Findings Across Key Secondary Endpoints Company to Host Conference Call and Webcast Tuesday May...

CYTK : 74.84 (-2.92%)
Cytokinetics Reports Monday: The Market Has Already Priced In What Hasn't Been Delivered

Barchart Research What to Expect from CYTK Earnings CYTK Generated May 4, 2026 Current Price $66.05 EPS Estimate $$-1.67 Consensus Rating Strong Buy Average Move 3.38% Cytokinetics Reports Monday: The...

CYTK : 74.84 (-2.92%)
Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026

Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced...

CYTK : 74.84 (-2.92%)
Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress

SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress...

CYTK : 74.84 (-2.92%)
Cytokinetics to Announce First Quarter Results on May 5, 2026

SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 5, 2026 at 4:00 PM...

CYTK : 74.84 (-2.92%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 15, 2026 it granted stock options to purchase an aggregate of 49,358...

CYTK : 74.84 (-2.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 85.38
2nd Resistance Point 82.19
1st Resistance Point 78.52
Last Price 74.84
1st Support Level 71.66
2nd Support Level 68.47
3rd Support Level 64.80

See More

52-Week High 80.20
Last Price 74.84
Fibonacci 61.8% 60.76
Fibonacci 50% 54.75
Fibonacci 38.2% 48.75
52-Week Low 29.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.